代谢功能障碍相关的肥胖性肝病与萨科佩尼亚之间的关联:系统性审查和元分析
Helai Hussaini1, Fikadu Woreta2, Olga Sarah3
1Internal Medicine, West Anaheim Medical Center, Anaheim, USA.
Cureus
|November 19, 2025
概括
与代谢功能障碍相关的脂肪性肝病 (MASLD) 患者的麻症患病率明显高于对照组. 建议在MASLD患者中进行例行查,以改善综合管理和肌肉健康.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 老年学是一门学科.
- 代谢疾病 代谢疾病
背景情况:
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 是一个日益严重的健康问题.
- 肉,肌肉质量和力量的损失,是老年人和患有慢性疾病的人的常见病症.
- 马斯尔德和肉症之间的关系需要进一步调查.
研究的目的:
- 与对照人群相比,系统地审查和元分析MASLD患者中肉类的患病率.
- 为了确定影响MASLD和肉类症之间的关联的因素.
主要方法:
- 从2015年1月到2025年8月,在主要数据库 (PubMed,Embase,Cochrane图书馆,Web of Science) 进行了全面的文献搜索.
- 包括16项研究,比较了MASLD患者和非MASLD对照患者的肉类的患病率.
- 随机效应模型用于元分析,以计算聚合赔率比率 (ORs).
主要成果:
- 分析显示,在MASLD患者 (14.86%) 与对照组 (6.49%) 之间,肉类的患病率显著更高,合并OR为2.24 (95%CI:1.74-2.89,p <0.001).
- 在各个研究中观察到实质性的异质性 (I2 = 95%).
- 亚组分析表明,在队列研究,50岁以下的人口和来自韩国和美国的研究中,相关性更强.
结论:
- 马斯尔德独立地与沙科佩尼亚患病率显著增加有关.
- 共有的病理生理机制,包括胰岛素抵抗和炎症,将MASLD与肉症联系在一起.
- 在MASLD患者中进行例行查和综合管理策略是有必要的.
相关概念视频
Overview of Lipid Metabolism
4.7K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.7K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
162
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
162
Metabolic States of the Body: Fasting and Starvation
2.7K
During the initial hours of fasting, the body uses up its glycogen stores as an energy source. Once these glycogen reserves are depleted, the body begins breaking down stored triglycerides and structural proteins. During this stage, glycerol becomes a key substrate for gluconeogenesis, while free fatty acids undergo beta-oxidation to provide energy for tissues, such as skeletal muscle. In the fasting state, the body spares protein breakdown as much as possible to conserve muscle and structural...
2.7K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
170
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
170
Overview of Carbohydrate Metabolism
3.2K
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
3.2K


